NasdaqGS:HSIC

Stock Analysis Report

Executive Summary

Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide.

Snowflake

Fundamentals

Solid track record with excellent balance sheet.


Similar Companies

Share Price & News

How has Henry Schein's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.2%

HSIC

6.2%

US Healthcare

0.5%

US Market


1 Year Return

-23.9%

HSIC

-5.7%

US Healthcare

6.8%

US Market

Return vs Industry: HSIC underperformed the US Healthcare industry which returned -5.7% over the past year.

Return vs Market: HSIC underperformed the US Market which returned 6.8% over the past year.


Shareholder returns

HSICIndustryMarket
7 Day-0.2%6.2%0.5%
30 Day-0.06%2.4%-0.8%
90 Day-5.9%-1.2%-0.9%
1 Year-2.9%-23.9%-4.2%-5.7%9.2%6.8%
3 Year5.0%-17.6%34.3%29.0%45.6%36.2%
5 Year35.9%6.6%65.1%55.2%63.2%45.4%

Price Volatility Vs. Market

How volatile is Henry Schein's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Henry Schein undervalued compared to its fair value and its price relative to the market?

20.6%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: HSIC ($62.81) is trading below our estimate of fair value ($79.15)

Significantly Below Fair Value: HSIC is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: HSIC is good value based on its PE Ratio (17.2x) compared to the Healthcare industry average (20.3x).

PE vs Market: HSIC is good value based on its PE Ratio (17.2x) compared to the US market (17.7x).


Price to Earnings Growth Ratio

PEG Ratio: HSIC is poor value based on its PEG Ratio (2.9x)


Price to Book Ratio

PB vs Industry: HSIC is overvalued based on its PB Ratio (3.3x) compared to the US Healthcare industry average (2.5x).


Next Steps

Future Growth

How is Henry Schein forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?

5.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HSIC's forecast earnings growth (5.9% per year) is above the savings rate (2.7%).

Earnings vs Market: HSIC's earnings (5.9% per year) are forecast to grow slower than the US market (14.6% per year).

High Growth Earnings: HSIC's earnings are forecast to grow, but not significantly.

Revenue vs Market: HSIC's revenue (2.4% per year) is forecast to grow slower than the US market (7.2% per year).

High Growth Revenue: HSIC's revenue (2.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HSIC's Return on Equity is forecast to be low in 3 years time (15.2%).


Next Steps

Past Performance

How has Henry Schein performed over the past 5 years?

0.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: HSIC's earnings have grown by 0.2% per year over the past 5 years.

Accelerating Growth: HSIC's earnings growth over the past year (56%) exceeds its 5-year average (0.2% per year).

Earnings vs Industry: HSIC earnings growth over the past year (56%) exceeded the Healthcare industry 5.3%.


Return on Equity

High ROE: HSIC's Return on Equity (15.5%) is considered low.


Return on Assets

ROA vs Industry: HSIC has a higher Return on Assets than the Healthcare industry average last year.


Return on Capital Employed

ROCE Improving: HSIC has improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is Henry Schein's financial position?


Financial Position Analysis

Short Term Liabilities: HSIC's short term assets ($3.1B) exceeds its short term liabilities ($1.8B)

Long Term Liabilities: HSIC's short term assets (3.1B) exceeds its long term liabilities (1.6B)


Debt to Equity History and Analysis

Debt Level: HSIC's debt to equity ratio (32.7%) is considered satisfactory

Reducing Debt: HSIC's debt to equity ratio has increased from 22.6% to 32.7% over the past 5 years.

Debt Coverage: HSIC's debt is well covered by operating cash flow (51.2%).

Interest Coverage: HSIC's interest payments on its debt are well covered by EBIT (17.8x coverage).


Balance Sheet

Inventory Level: HSIC has a high level of physical assets or inventory.

Debt Coverage by Assets: HSIC's debt is covered by short term assets (assets are 2.546160x debt).


Next Steps

  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Henry Schein's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.6%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate HSIC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate HSIC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if HSIC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HSIC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HSIC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Henry Schein's salary, the management and board of directors tenure and is there insider trading?

7.8yrs

Average management tenure


CEO

Stanley Bergman (69yo)

30.8yrs

Tenure

US$6,481,739

Compensation

Mr. Stanley M. Bergman has been the Chief Executive Officer and Executive Chairman of Henry Schein, Inc. since 1989. Mr. Bergman has been an Executive Director of Henry Schein, Inc. since 1982. He served a ...


CEO Compensation Analysis

Compensation vs. Market: Stanley's total compensation ($USD6.48M) is about average for companies of similar size in the US market ($USD6.81M).

Compensation vs Earnings: Stanley's compensation has been consistent with company performance over the past year.


Management Age and Tenure

7.8yrs

Average Tenure

62.5yo

Average Age

Experienced Management: HSIC's management team is seasoned and experienced (7.8 years average tenure).


Board Age and Tenure

18.3yrs

Average Tenure

65.5yo

Average Age

Experienced Board: HSIC's board of directors are seasoned and experienced ( 18.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$1,494,78520 Jun 19
Steven Paladino
EntityIndividual
Role
Member of the Board of Directors
Executive VP
Shares20,712
Max PriceUS$72.17
SellUS$1,413,75320 Jun 19
Gerald Benjamin
EntityIndividual
Role
Member of the Board of Directors
Executive VP
Shares19,630
Max PriceUS$72.02
SellUS$249,14014 Jun 19
E. Rekow
EntityIndividual
Shares3,500
Max PriceUS$71.21
SellUS$124,74813 Jun 19
Paul Brons
EntityIndividual
Shares1,758
Max PriceUS$70.96
SellUS$64,88813 Mar 19
Philip Laskawy
EntityIndividual
Role
Lead Director
Lead Director
Shares1,084
Max PriceUS$59.86
SellUS$212,30706 Mar 19
Philip Laskawy
EntityIndividual
Role
Lead Director
Lead Director
Shares3,591
Max PriceUS$59.12
BuyUS$121,19026 Feb 19
Anne Margulies
EntityIndividual
Shares2,000
Max PriceUS$60.60
SellUS$626,37312 Dec 18
Michael Ettinger
EntityIndividual
Shares7,425
Max PriceUS$84.36
SellUS$5,955,99707 Dec 18
Stanley Bergman
EntityIndividual
Role
Chief Executive Officer
Executive Chairman & CEO
Shares69,000
Max PriceUS$89.07
SellUS$1,901,16704 Dec 18
Steven Paladino
EntityIndividual
Role
Member of the Board of Directors
Executive VP
Shares21,110
Max PriceUS$90.06
SellUS$738,65503 Dec 18
David McKinley
EntityIndividual
Shares8,321
Max PriceUS$88.77

Ownership Breakdown


Management Team

  • Stanley Bergman (69yo)

    Executive Chairman & CEO

    • Tenure: 30.8yrs
    • Compensation: US$6.48m
  • Steven Paladino (62yo)

    Executive VP

    • Tenure: 26.8yrs
    • Compensation: US$2.65m
  • James Breslawski (65yo)

    Vice Chairman & President

    • Tenure: 1.4yrs
    • Compensation: US$2.75m
  • Gerald Benjamin (66yo)

    Executive VP

    • Tenure: 25.1yrs
    • Compensation: US$2.65m
  • Mark Mlotek (63yo)

    Executive VP

    • Tenure: 24.1yrs
    • Compensation: US$2.48m
  • Walter Siegel (59yo)

    Senior VP & General Counsel

    • Tenure: 6yrs
  • Gerard Meuchner (56yo)

    Chief Global Communications Officer & VP

    • Tenure: 7.7yrs
  • Carolynne Borders

    Vice President of Investor Relations

    • Tenure: 6.9yrs
  • Ronald South

    Chief Accounting Officer & VP of Corporate Finance

    • Tenure: 0yrs
  • Chris Pendergast (56yo)

    Senior VP & CTO

    • Tenure: 1.5yrs

Board Members

  • Phil Laskawy (78yo)

    Lead Director

    • Tenure: 7.8yrs
    • Compensation: US$314.40k
  • Stanley Bergman (69yo)

    Executive Chairman & CEO

    • Tenure: 30.8yrs
    • Compensation: US$6.48m
  • Steven Paladino (62yo)

    Executive VP

    • Tenure: 26.8yrs
    • Compensation: US$2.65m
  • James Breslawski (65yo)

    Vice Chairman & President

    • Tenure: 1.4yrs
    • Compensation: US$2.75m
  • Gerald Benjamin (66yo)

    Executive VP

    • Tenure: 25.1yrs
    • Compensation: US$2.65m
  • Mark Mlotek (63yo)

    Executive VP

    • Tenure: 24.1yrs
    • Compensation: US$2.48m
  • Joe Herring (63yo)

    Independent Director

    • Tenure: 3.4yrs
    • Compensation: US$291.40k
  • Louis Sullivan (86yo)

    Chairman of Medical Advisory Board

    • Tenure: 13.3yrs
    • Compensation: US$225.87k
  • Barry Alperin (79yo)

    Independent Director

    • Tenure: 23.4yrs
    • Compensation: US$308.40k
  • Brad Sheares (62yo)

    Independent Director

    • Tenure: 9.8yrs
    • Compensation: US$282.18k

Company Information

Henry Schein, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Henry Schein, Inc.
  • Ticker: HSIC
  • Exchange: NasdaqGS
  • Founded: 1932
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: US$9.312b
  • Shares outstanding: 148.26m
  • Website: https://www.henryschein.com

Number of Employees


Location

  • Henry Schein, Inc.
  • 135 Duryea Road
  • Melville
  • New York
  • 11747
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HSICNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 1995
HS2DB (Deutsche Boerse AG)YesCommon StockDEEURNov 1995
HSICWBAG (Wiener Boerse AG)YesCommon StockATEURNov 1995

Biography

Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/20 23:42
End of Day Share Price2019/10/18 00:00
Earnings2019/06/29
Annual Earnings2018/12/29


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.